Can a Genetic Test Help Choose the Right Antidepressant? Understanding Pharmacogenomic Testing
Genetic tests promise to match you with the right antidepressant. Here is what pharmacogenomic testing can and cannot do, according to the evidence.
Dr. Timothy Carpenter
8/20/20263 min read
Finding the right antidepressant can feel like a long process of trial and error. Only about forty percent of people feel relief from the first antidepressant they try, which means many patients cycle through more than one medication before landing on something that works. It is frustrating, and sometimes discouraging. So it is no surprise that pharmacogenomic testing, often marketed as a way to take the guesswork out of prescribing, has become one of the most talked about ideas in psychiatry. Here is a clear eyed look at what it can and cannot do.
What pharmacogenomic testing actually measures
Pharmacogenomic testing, sometimes shortened to PGx, looks at variations in specific genes that affect how your body processes medications. In psychiatry, the most relevant genes are liver enzymes with names like CYP2D6 and CYP2C19. Depending on your genetic makeup, you might break certain medications down quickly, slowly, or somewhere in between. That can influence how much of a drug ends up in your system and, in turn, how likely you are to experience side effects at a standard dose. A test usually involves a simple cheek swab or blood sample.
What the evidence supports
There is real science here, and it is worth taking seriously. National and international bodies, including the Clinical Pharmacogenetics Implementation Consortium and the FDA, recognize that certain gene and medication pairings can guide dosing. FDA labeling for a number of antidepressants already includes pharmacogenomic information. Some randomized trials and a meta-analysis of thirteen studies covering nearly five thousand patients with major depression found that genetically guided treatment was associated with a meaningfully higher likelihood of remission compared with standard prescribing. Real world analyses of large patient groups have also suggested testing can reduce the use of poorly tolerated medications.
The important caveats
This is where honesty matters, because the marketing sometimes runs ahead of the science. The evidence is strongest for how you metabolize a drug, which mostly informs dosing and side effect risk. It is much weaker for predicting which specific antidepressant will lift your depression. The FDA has cautioned against tests that overstate their ability to identify the single best medication, noting that for many genes the link to antidepressant effectiveness has not been firmly established. Expert reviews continue to conclude that routine testing for every patient starting an antidepressant is not currently recommended, and results should support a clinician's judgment rather than replace it.
Who might benefit most
Pharmacogenomic testing tends to be most useful for people who have already tried several antidepressants without success, or who have experienced unusual or severe side effects that hint at atypical metabolism. In those situations, understanding how you process medications can add a helpful piece to the puzzle. For someone starting treatment for the first time, it is usually not necessary.
The bottom line
Think of pharmacogenomic testing as a useful tool, not a crystal ball. It can help a knowledgeable provider fine tune dosing and avoid certain pitfalls, but it does not eliminate the personalized, collaborative work of finding the right treatment. If you have struggled to find an antidepressant that fits, a conversation with a psychiatric provider at Birmingham Psychiatry and Behavioral Health can help you decide whether testing makes sense for your situation, and how to interpret the results wisely.
This article is for educational purposes and is not medical advice. Decisions about medication and genetic testing should be made with a qualified psychiatric provider who knows your history.
References
1. Bousman CA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants. Clinical Pharmacology and Therapeutics, 2023.
2. Brown LC, et al. Meta-analysis of the effect of pharmacogenomic-guided treatment on remission in major depressive disorder, 2022.
3. An Overview of Pharmacogenomic Testing for Psychiatric Disorders. NCBI Bookshelf, 2023.
4. Pharmacogenomic Testing Brings Real-World Benefits for Depression Treatment. UTHealth Houston Department of Psychiatry, 2025.
5. Psychiatric Pharmacogenomic Testing: The Evidence Base. Psychiatric Times, 2026, including FDA safety communication guidance.
BPBH
Empowering adults with compassionate mental health care.
Connect with us!
© 2025. All rights reserved.